INTRODUCTION
============

Secondary hyperparathyroidism (SHPT) is one of the most important complications in chronic kidney disease-mineral and bone disorder (CKD-MBD). Patients are considered to have severe SHPT when serum phosphate (P), serum calcium (Ca) and intact parathyroid hormone (PTH) levels can no longer be adequately controlled by medical management and when clinical symptoms are associated with a significantly increased risk of cardiovascular morbidity and mortality \[[@sfy062-B1]\]. Cinacalcet hydrochloride (C-HCl) is a calcimimetic agent for SHPT treatment that increases the sensitivity of Ca-sensing receptors (CaSRs) to activation by extracellular Ca and thus suppresses PTH release while simultaneously controlling other mineral biochemical parameters \[[@sfy062-B4], [@sfy062-B5]\]. C-HCl has the potential to control biochemical parameters, even in cases of severe SHPT refractory to conventional treatments with Ca supplements, P binders and active vitamin D analogues. However, in some patients, C-HCl seems to be either only partially effective or ineffective \[[@sfy062-B6], [@sfy062-B7]\], and this case report discusses key points that could explain this, including the presence of severe SHPT and non-compliance to treatment.

CASE REPORT
===========

A 12-year-old Moroccan female who presented a nephrotic syndrome was treated with corticosteroids, without any effect. A renal biopsy performed 8 years later showed typical focal glomerulosclerosis. Renal insufficiency developed rapidly, with the concomitant development of cardiac failure. Dialysis was required at the age of 22 years. Two years later the patient moved to France and was dialysed in our unit. Dialysis was carried out via an arteriovenous fistula and comprised 4-h sessions three times a week, with a dialysate Ca level consistently maintained at 1.5 mmol/L. When the patient first presented in our unit, our main concern was severe cardiac failure due to uraemic cardiomyopathy, with a left ventricular ejection fraction (LVEF) of 28%. After a few months, following treatment adjustment using diuretics, β-blockers and angiotensin-converting enzyme (ACE) inhibitors, as well as a decrease in body weight, the LVEF improved to 54%. The next important problem was SHPT. The main biological parameters and medications prescribed to the patient are shown in [Table 1](#sfy062-T1){ref-type="table"}. Despite an increase in the dosage of C-HCl, the level of PTH did not decrease but paradoxically increased. To ensure that the prescribed doses were effectively taken by the patient, the medication was given at the dialysis unit on the days of dialysis at the end of the dialysis session. However, the level of PTH consistently increased.

In May 2007, an ultrasound scan of the parathyroid glands revealed normal upper right and upper left parathyroids of \~3 mm in diameter and two enlarged parathyroids, with the right lower gland measuring 8 × 6 × 5.2 mm and the left lower gland measuring 7 × 6 × 4.5 mm. Consequently, a parathyroidectomy was performed in July 2007, at a preoperative PTH level of 2162 pg/mL. The two upper parathyroid glands were slightly hyperplastic but were left intact and controlled with a clip to ensure that they could be easily identified, if necessary. The two lower glands, each \~10 mm in diameter, were resected, with each gland weighing 5.3 and 5.2 g, respectively. The histopathological examination revealed the presence of a benign parathyroid adenoma consisting of chief cells in each resected gland; however, 30--40% of each gland contained oxyphil cells, which was classified as an oxyphil adenoma ([Figure 1](#sfy062-F1){ref-type="fig"}), and a parathyroid carcinoma was excluded.

Two hours post-surgery, the serum Ca level dropped to 1.30 mmol/L and the PTH level to 8 pg/mL. The patient was prescribed 12 g/day of intravenous Ca and 6 µg/day of alfacalcidol. Four months later, with a treatment regimen of 4 g/day of Ca and 4 µg/day of alfacalcidol, the Ca level was 2.00 mmol/L, P level 1.20 mmol/L and PTH level 22 pg/mL. In the following year, the patient received a kidney transplant, was pregnant 3 years later and remained well 9 years later, with a creatinine level of 118 µmol/L, Ca level of 2.36 mmol/L and PTH level of 36 pg/ml on a treatment regimen of 2 g/day of Ca and 2 µg/day of alfacalcidol.

![(**A**) The chief cells have an amphophilic, vacuolated cytoplasm. (**B**) The oxyphil cells are composed of large cells with a brightly stained eosinophilic granular cytoplasm. The bar at the bottom represents 1 mm (magnitude ×100).](sfy062f1){#sfy062-F1}

###### 

Main biological parameters and medications prescribed to the patient after her arrival in the dialysis unit

  Parameters                           15 June 2005   7 December 2005   07 March 2006   10 June 2006   15 September 2006   6 December 2006   24 May 2007   Post- surgery   6 December 2007   March 2018
  ----------------------------------- -------------- ----------------- --------------- -------------- ------------------- ----------------- ------------- --------------- ----------------- ------------
  Body weight (kg)                         48.5             43               42              43              42.5                42              42             42               44              56
  Calcium level (mmol/L)                   2.19            2.21             2.10            2.25             2.32               2.28            2.32           1.30             2.00            2.36
  Phosphate level (mmol/L)                 1.56            2.15             2.19            1.80             1.78               1.64            1.62           1.52             1.26            1.06
  Alkaline phosphatase (IU/L)               62              89               79             110               120                130             165            110              57              46
  PTH (pg/mL)                              776              808             1065            1347             1207               1475            1869             8               15              36
  *Kt*/*V*                                 1.78            1.88             1.69            1.73             1.79               1.67            1.72            --              1.76             --
  Alfacalcidol (µg/day)                     1                1                1              1                 1                  1               1              6                4              2
  Calcium carbonate (g/day)                1.5              1.5              1.5            1.5               1.5                1.5             1.5          12 (IV)            4.5             2
  Sevelamer (mg/day)                        --             3200             4800            7200             7200               7200            7200            --              2400             --
  Cinacalcet hydrochloride (mg/day)         --              --               30              60               90                 120             150            --               --              --

IV, intravenous.

DISCUSSION
==========

This case report raises many important points of discussion: the presence of SHPT, the patient's compliance with numerous medications, the presence of an oxyphil cell parathyroid adenoma and the role of C-HCl in the histologic type of parathyroid adenoma.

SHPT is a common, serious and progressive complication of CKD-MBD. It is mainly characterized by high serum PTH levels, parathyroid gland hyperplasia and disturbance in mineral metabolism characterized mainly by hypocalcaemia and hyperphosphataemia. Initial treatment of SHPT in haemodialysis (HD) patients usually includes Ca salts, intestinal P binders and vitamin D derivatives. The oral calcimimetic C-HCl is often used later in the course of the disease in patients who fail to respond adequately to the initial treatments. C-HCl has been shown to be effective in reducing circulating PTH levels in HD patients with SHPT in several clinical trials \[[@sfy062-B8]\]. Overall, treatment with C-HCl was associated with significant reductions in the total volume of parathyroid glands, with a corresponding decrease in PTH levels \[[@sfy062-B6]\]. In another study, Meola *et al*. \[[@sfy062-B15]\] found that C-HCl, in combination with conventional treatments, led to an improvement in biochemical and clinical parameters of SHPT and reduced glandular volume in patients with severe SHPT.

The median number of medications prescribed to HD patients is significant at \~19 pills/day \[[@sfy062-B16]\]. Prescription of P binders makes up around half of the medications prescribed per day. However, the frequency distribution of adherence to P binders is \~40% \[[@sfy062-B16]\]. Some patients appear to be insensitive to or exhibit hyporesponsiveness to C-HCl treatment. One explanation could be simply a lack of compliance with treatment and/or inadequate treatment education provided to these patients. In a recent European retrospective observational study \[[@sfy062-B17]\], it was observed that 23% of the incident patients had their C-HCl treatment discontinued after 1 year. One of the causes of hyporesponsiveness could be the number, size and nodular hyperplastic characteristic of the parathyroid glands, which are known to predict the response to C-HCl. Another possibility of failed treatment with C-HCl could be the development of an oxyphil cell parathyroid adenoma.

Oxyphil cell parathyroid adenomas are rare. In 1967 it was postulated by Christie \[[@sfy062-B18]\] that the development of oxyphil cells may be a defence mechanism in which oxyphil cells may produce a hormone necessary for maintaining 'a normal biochemical milieu in adverse circumstances in particular in CKD where gross electrolyte imbalance is likely to occur'. Oxyphil cell content is markedly increased in CKD; in general, the proportion of oxyphil cells increases in parallel with the total weight of the parathyroid glands in uraemic patients, suggesting that this cell type is sensitive to stimulation \[[@sfy062-B19]\]. Recent studies have found an association between treatment of SHPT with calcitriol and/or C-HCl and an even higher oxyphil cell content of the parathyroid glands than in the absence of such treatment \[[@sfy062-B20]\]. A recent study by Ritter *et al.* \[[@sfy062-B21]\] shed new light on the role and function of oxyphil cells. The study analysed patients who underwent parathyroidectomy for SHPT after treatment with paricalcitol and/or C-HCl. The main findings were: The parathyroid tissue in uraemic patients had, on average, five times higher oxyphil cell content than normal parathyroid tissue.Conventional pharmacological treatment of SHPT could have affected the cell population of the parathyroid glands in uraemic patients.Among treated patients, the parathyroid tissue in the C-HCl group showed a significantly higher content of oxyphil cells (26.7 ± 14.2%) compared with the paricalcitol group (6.9 ± 5.1%); however, the cubic volume of the parathyroid glands in both groups was similar. In our case, the oxyphil cell content was \~40%.

These data indicate that the two conventional treatments for SHPT, i.e. C-HCl and paricalcitol, may have disparate effects on parathyroid tissue composition. However, one of the main questions is the function of parathyroid oxyphil cells in SHPT and the role of C-HCl in the development of these cells. It seems that the oxyphil cells express more CaSRs compared with chief cells, and Ritter *et al.* \[[@sfy062-B19]\] postulated that CaSRs and calcimimetics may play a role in the transdifferentiation of chief cells to oxyphil cells. In another paper, Ritter *et al*. \[[@sfy062-B22]\] showed that oxyphil cells overexpress parathyroid tissue genes encoding, for example, PTH, calcium-sensing receptor, glial cells missing homolog 2 and parathyroid hormone--related protein.

Moreover, it was reported by the same group that human parathyroid oxyphil cells consistently expressed high levels of 1α-OHase protein compared with parathyroid chief cells \[[@sfy062-B22]\]. C-HCl directly increased parathyroid 1α-OHase expression in cultured parathyroid cells. The importance of Ca in the regulation of 1α-OHase is also clinically important because calcimimetics are commonly used to treat patients with SHPT. The oxyphil:chief cell ratio was increased by C-HCl treatment \[[@sfy062-B20]\]. The conversion of chief cells to oxyphil cells may be a compensatory mechanism by which increased local production of calcitriol could act to decrease PTH levels. Because C-HCl directly activates the response of CaSRs to extracellular Ca and calcitriol can activate CaSRs indirectly via its calcaemic effect, these actions may play a role in the transdifferentiation of chief cells to oxyphil cells. The complex balance between chief and oxyphil cells could, at least partly, be determined by an autocrine/paracrine regulation of the activity of chief cells by oxyphil cells \[[@sfy062-B24]\]. C-HCl could also induce apoptosis and necrosis of parathyroid glands, as demonstrated by Sumida *et al.* \[[@sfy062-B23]\], with a significant increase in oxyphil cell area and haemosiderosis score. These results suggest that C-HCl could induce specific qualitative alterations in hyperplastic parathyroid glands in patients with severe SHPT. Lomonte *et al*. \[[@sfy062-B20]\] suggested that the change in the oxyphil:chief cell ratio was probably due to a significant decrease in the proportion of chief cells accelerated by C-HCl through an apoptotic mechanism in uraemic rats \[[@sfy062-B24], [@sfy062-B25]\]. It is possible that C-HCl has a qualitative influence on parathyroid cells and induces pathological changes.

Clearly further studies are required to determine the role of C-HCl in the chief-to-oxyphil cell transdifferentiation and the consequent influence on parathyroid gland function following treatment of SHPT in CKD patients as well as the possible role of oxyphil cells in attenuating or inactivating the role of C-HCl in the control of SHPT.
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